Hints and tips:
...Two of Unilever’s largest investors have called for radical shake-up of the company or its board in the wake of its abortive £50bn pursuit of GlaxoSmithKline’s consumer health business....
...Its attempted shake-up at Brentford-based healthcare group GlaxoSmithKline was blocked by the company’s board, which rejected Elliott’s demands to appoint new directors and re-evaluate whether chief executive...
...For Emma Walmsley, the chief executive of underperforming UK drugmaker GlaxoSmithKline since 2017, the pressure is on to placate her unexpected guests....
...As of March, only five FTSE 100 companies had female CEOs: GlaxoSmithKline, Imperial Brands, ITV, Severn Trent and Whitbread....
...Accustomed to taking three puffs a day from two different inhalers, supplemented by a third, she now takes a once-a-day treatment devised by the UK pharma group GlaxoSmithKline....
...GlaxoSmithKline, on the other hand, has advanced its anti-corruption initiatives after a bribery scandal in China forced a clean-up at the company, says Ms Schaik....
...Activist battles 2: Innoviva THE BUSINESS A respiratory drug company that receives royalties from GlaxoSmithKline for its asthma medications....
...Corporate earnings reports out today include Sage, Hammerson, Compass, GlaxoSmithKline, GKN, ITV, Metrobank, Tullow Oil, Brewin Dolphin and Jupiter Fund Management....
...To whit, the government’s appointment of Sir Philip Hampton, GlaxoSmithKline chairman and general corporate grandee, to address the paucity of managing females in UK companies....
...A full auction has begun with GlaxoSmithKline, Sanofi and Galenica of Switzerland among the potential bidders, the people said....
...In April CRISPR Therapeutics, a rival company, raised $64m from investors including Celgene, a prolific investor in biotech groups, and the venture capital arm of GlaxoSmithKline....
...The FTSE 100’s largest five companies (HSBC, Royal Dutch Shell, BP, GlaxoSmithKline and British American Tobacco) – which account for a combined 26 per cent of the index – are all well-established presences...
...Private equity groups are exploring a $10bn plan to buy hundreds of older drug brands from GlaxoSmithKline and Sanofi and merge them, highlighting the continued intense deal activity sweeping the pharmaceuticals...
...GlaxoSmithKline and Roche struck similar deals with the Oxfordshire-based company last year to collaborate on drugs that help the immune system identify and attack cancer cells....
...(Financial Times) Deals fever grips pharmaceuticals industry: A near $50bn takeover battle for the maker of Botox and a multibillion-dollar asset swap between Novartis and GlaxoSmithKline have intensified...
...GSK shakes up sales practices GlaxoSmithKline this week unveiled plans to scrap individual sales targets for its marketing employees around the world, as part of efforts to remove incentives perceived...
...follows Elan’s planned $1bn payment to Theravance, a US-based biotech business, to acquire 21 per cent of the future royalties on four of its experimental respiratory medicines developed in partnership with GlaxoSmithKline...
...The good news for Elan shareholders is that the drugs are being developed by GlaxoSmithKline, which owns 27 per cent of Theravance....
...have adopted a range of responses, most encompassing managerial efforts to boost accountability, increase incentives and cut the size of research units to create a more entrepreneurial feeling, such as GlaxoSmithKline...
...(Financial Times) GlaxoSmithKline is considering cutting prescription-linked commissions paid to its sales staff and reducing drug prices in China amid the fall-out from a growing corruption probe....
...Potential bidders for Bausch & Lomb include Abbot Group, Merck, Sanofi, Bayer, Pfizer, and GlaxoSmithKline. News of the potential sale was first reported by Bloomberg....
...Only five companies – Royal Dutch Shell, Vodafone, HSBC, GlaxoSmithKline and BP accounted for more than one-third of all the dividends paid, and just 15 made up almost three-fifths of the total....
...GlaxoSmithKline is emptying out tens of millions of euros each day from its bank accounts in Europe’s more fragile countries in order to minimise the risk of exposure to a regional banking or financial crisis...
...Backed by industry heavyweights including Sir Richard Sykes, former chairman of GlaxoSmithKline, NCPharma is targeting annualised returns of more than 28 per cent, and a stock market listing within five...
...In fact, many of the larger groups are reflecting this approach, with GlaxoSmithKline, Pfizer and AstraZeneca among those that have focused on increasing returns to shareholders while cutting back on R&D...
International Edition